CY1111808T1 - Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια - Google Patents
Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργιαInfo
- Publication number
- CY1111808T1 CY1111808T1 CY20111100859T CY111100859T CY1111808T1 CY 1111808 T1 CY1111808 T1 CY 1111808T1 CY 20111100859 T CY20111100859 T CY 20111100859T CY 111100859 T CY111100859 T CY 111100859T CY 1111808 T1 CY1111808 T1 CY 1111808T1
- Authority
- CY
- Cyprus
- Prior art keywords
- results
- preventive
- compositions
- arachidonic acid
- diseases
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000003449 preventive effect Effects 0.000 title abstract 2
- 210000004556 brain Anatomy 0.000 title 1
- 238000001356 surgical procedure Methods 0.000 title 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 8
- 229940114079 arachidonic acid Drugs 0.000 abstract 4
- 235000021342 arachidonic acid Nutrition 0.000 abstract 4
- 239000000470 constituent Substances 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 1
- 229930186217 Glycolipid Natural products 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- -1 alcohol ester Chemical class 0.000 abstract 1
- 230000003925 brain function Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Σκοπός της παρούσας εφεύρεσης είναι η παροχή μιας σύνθεσης που έχει προληπτική ή βελτιωτική δράση σε συμπτώματα ή νόσους που προκαλούνται από μειωμένη εγκεφαλική λειτουργία. Αυτή η σύνθεση περιέχει, ως το δραστικό της συστατικό, αραχιδονικό οξύ ή/και μια ένωση που έχει αραχιδονικό οξύ ως ένα συστατικό λιπαρό οξύ και, ιδιαίτερα, έναν αλκοολικό εστέρα αραχιδονικού οξέος ή ένα τριγλυκερίδιο, φωσφολιπίδιο ή γλυκολιπίδιο στο οποίο το σύνολο ή ένα μέρος των συστατικών λιπαρών οξέων είναι αραχιδονικό οξύ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001235519A JP2003048831A (ja) | 2001-08-02 | 2001-08-02 | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
EP02716453A EP1419768B1 (en) | 2001-08-02 | 2002-01-29 | Compositions having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111808T1 true CY1111808T1 (el) | 2015-10-07 |
Family
ID=19066953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100859T CY1111808T1 (el) | 2001-08-02 | 2011-09-07 | Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια |
Country Status (13)
Country | Link |
---|---|
US (1) | US10744146B2 (el) |
EP (1) | EP1419768B1 (el) |
JP (1) | JP2003048831A (el) |
KR (2) | KR20170109693A (el) |
CN (2) | CN1561206A (el) |
AT (1) | ATE520395T1 (el) |
AU (1) | AU2008201045B2 (el) |
CA (1) | CA2456049C (el) |
CY (1) | CY1111808T1 (el) |
DK (1) | DK1419768T3 (el) |
ES (1) | ES2369074T3 (el) |
PT (1) | PT1419768E (el) |
WO (1) | WO2003013497A1 (el) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070004670A1 (en) * | 1998-07-31 | 2007-01-04 | Richard Wurtman | Compositions containing citicoline, and methods of use thereof |
US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
EP1542670B2 (en) * | 2002-09-24 | 2023-07-05 | Suntory Holdings Limited | Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities in adults |
US9782377B2 (en) | 2003-03-27 | 2017-10-10 | Suntory Holdings Limited | Composition for normalization of infradian rhythm |
KR101362989B1 (ko) | 2003-03-27 | 2014-02-17 | 산토리 홀딩스 가부시키가이샤 | 지질 개선제 및 지질 개선제를 함유하는 조성물 |
GB0311081D0 (en) | 2003-05-14 | 2003-06-18 | Btg Internat Limted | Treatment of neurodegenerative conditions |
GB2442164B (en) * | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Treatment of neurodegenerative conditions |
GB0319358D0 (en) * | 2003-08-18 | 2003-09-17 | Btg Int Ltd | Treatment of neurodegenerative conditions |
CH698539A8 (de) | 2003-08-18 | 2009-10-15 | Btg Int Ltd | Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. |
GB2442161B (en) * | 2003-08-18 | 2008-05-21 | Btg Int Ltd | Triglycerides |
JP4522075B2 (ja) | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
TWI365716B (en) * | 2003-12-02 | 2012-06-11 | Suntory Holdings Ltd | Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same |
EP1713463A4 (en) * | 2004-01-19 | 2009-03-18 | Martek Biosciences Corp | REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES |
US7847113B2 (en) | 2004-03-01 | 2010-12-07 | Suntory Holdings Limited | Phospholipids including long-chain polyunsaturated fatty acids as constituents, and use of such phospholipids |
JP2008509660A (ja) | 2004-08-12 | 2008-04-03 | サントリー株式会社 | 新規な菌株保存技術を用いた高度不飽和脂肪酸の製造方法 |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
US8241868B2 (en) | 2005-02-08 | 2012-08-14 | Nippon Suisan Kaisha, Ltd. | Production of polyunsaturated fatty acids using cell treatment method |
JP4849806B2 (ja) | 2005-02-08 | 2012-01-11 | 日本水産株式会社 | 新規な菌体処理方法を用いた高度不飽和脂肪酸の製造方法 |
GB0504362D0 (en) | 2005-03-02 | 2005-04-06 | Btg Int Ltd | Cytokine modulators |
JP5566603B2 (ja) * | 2005-05-23 | 2014-08-06 | マサチューセッツ インスティテュート オブ テクノロジー | Pufaを含有する組成物及びそれを使用した方法 |
JP5967855B2 (ja) * | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
JP5697293B2 (ja) * | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
CN101277739B (zh) * | 2005-09-30 | 2013-01-02 | 雀巢技术公司 | 用于增强认知功能的方法和组合物 |
EP1772146A1 (en) * | 2005-10-03 | 2007-04-11 | Neuropharma, S.A. | Polyunsaturated fatty acids as bace inhibitors |
DE102005058369A1 (de) * | 2005-12-06 | 2007-06-14 | Lts Lohmann Therapie-Systeme Ag | Ungesättigte Fettsäuren als Thrombin-Inhibitoren |
JP5050195B2 (ja) * | 2006-02-14 | 2012-10-17 | 国立大学法人 岡山大学 | 神経細胞分化誘導剤 |
KR20090003148A (ko) * | 2006-04-03 | 2009-01-09 | 액세라인크 | 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도 |
WO2008081989A1 (ja) | 2006-12-28 | 2008-07-10 | Suntory Holdings Limited | 神経再生剤 |
EP2144618B1 (en) | 2007-03-28 | 2013-05-15 | Aker Biomarine ASA | Bioeffective krill oil compositions |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
US20090023808A1 (en) * | 2007-06-29 | 2009-01-22 | Martek Biosciences Corporation | Production and Purification of Esters of Polyunsaturated Fatty Acids |
JP2009019025A (ja) * | 2007-07-13 | 2009-01-29 | Suntory Ltd | 非ヒト動物の老化又は痴呆に伴う疾患又は症状の改善剤 |
PT2650380E (pt) | 2007-07-31 | 2016-01-14 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
CA2729622C (en) | 2008-07-03 | 2017-07-25 | Accera, Inc. | Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders |
US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
JP2009219500A (ja) * | 2009-06-22 | 2009-10-01 | Suntory Holdings Ltd | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
JP2011136948A (ja) * | 2009-12-28 | 2011-07-14 | Nisshin Oillio Group Ltd | うつ病又はうつ状態の予防又は治療用油脂組成物 |
AU2014203179C1 (en) | 2013-06-14 | 2017-05-04 | Aker Biomarine Antarctic As | Lipid extraction processes |
US9216199B2 (en) | 2013-12-05 | 2015-12-22 | Buriva, LLC | Nutritional supplement containing phospholipid-DHA derived from eggs |
US9610302B2 (en) | 2013-12-05 | 2017-04-04 | Buriva, LLC. | Composition containing phospholipid-DHA and B vitamins |
US9549937B2 (en) | 2013-12-05 | 2017-01-24 | Burvia, LLC. | Composition containing phospholipid-DHA and folate |
US9233114B2 (en) | 2013-12-05 | 2016-01-12 | Buriva, LLC | Dietary supplement containing phospholipid-DHA derived from eggs |
GB201400431D0 (en) | 2014-01-10 | 2014-02-26 | Aker Biomarine As | Phospholipid compositions and their preparation |
CN113908269A (zh) | 2014-05-23 | 2022-01-11 | 塞尔德克斯医疗公司 | 嗜酸性粒细胞或肥大细胞相关病症的治疗 |
JP6095615B2 (ja) * | 2014-07-22 | 2017-03-15 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
AU2016217566B2 (en) | 2015-02-11 | 2019-02-14 | Aker Biomarine Human Ingredients As | Lipid compositions |
KR20170118125A (ko) | 2015-02-11 | 2017-10-24 | 에이커 바이오마린 앤탁틱 에이에스 | 지질 추출 공정 |
JP2016172770A (ja) * | 2016-06-29 | 2016-09-29 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
US10456368B2 (en) | 2016-09-26 | 2019-10-29 | Garrett E. Wdowin | Compositions for mitigating brain trauma and methods thereof |
CN110747239B (zh) * | 2019-11-26 | 2021-06-22 | 瞿瀚鹏 | 富含Sn-2位ARA的微生物油脂及其制备方法和应用 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB111282A (en) | 1916-11-10 | Ets De Dion Bouton | Improvements in or relating to Roller Bearings. | |
US4668704A (en) * | 1982-08-09 | 1987-05-26 | Regents Of The University Of California | Method for protecting and healing gastro-duodenal mucosa and the liver of mammals |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
GB8601915D0 (en) | 1986-01-27 | 1986-03-05 | Efamol Ltd | Pharmaceutical compositions |
JPS63297342A (ja) | 1987-05-28 | 1988-12-05 | Nisshin Oil Mills Ltd:The | 合成油脂ならびにこれを含有する脂肪乳剤輸液および経腸栄養剤 |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
GB8714772D0 (en) | 1987-06-24 | 1987-07-29 | Efamol Ltd | Essential fatty acid compositions |
US5658767A (en) | 1991-01-24 | 1997-08-19 | Martek Corporation | Arachidonic acid and methods for the production and use thereof |
GB9224809D0 (en) | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
GB9300125D0 (en) * | 1993-01-06 | 1993-03-03 | Scotia Holdings Plc | Compositions containing esters of unsaturated fatty acids |
AU673700B2 (en) * | 1993-01-27 | 1996-11-21 | Scotia Holdings Plc | Triglycerides |
JP3467794B2 (ja) | 1993-03-09 | 2003-11-17 | 日本油脂株式会社 | 学習能向上剤 |
AU7053494A (en) | 1993-06-04 | 1995-01-03 | Martek Biosciences Corporation | Method of treating coronary vascular disease using docosahexaenoic acid |
ATE264099T1 (de) | 1993-06-09 | 2004-04-15 | Martek Biosciences Corp | Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen |
CA2201931C (en) | 1994-10-05 | 2004-08-10 | Gerhard Kohn | Mixture of phospholipid-containing fats and lcp fatty acids |
JPH08143454A (ja) | 1994-11-17 | 1996-06-04 | Kanagawa Kagaku Kenkyusho:Kk | 神経成長因子産生増強剤 |
GB9423625D0 (en) | 1994-11-23 | 1995-01-11 | Scotia Holdings Plc | Fortified fruit juice |
US5583019A (en) * | 1995-01-24 | 1996-12-10 | Omegatech Inc. | Method for production of arachidonic acid |
JPH08214891A (ja) | 1995-02-17 | 1996-08-27 | Osaka City | 高度不飽和脂肪酸含有トリグリセリドを含む油脂の製造方法 |
EP1886679A3 (en) | 1995-06-07 | 2008-05-28 | Martek Biosciences Corporation | Methods for controlling highly unsaturated fatty acid content in various tissues |
JPH0923817A (ja) | 1995-07-07 | 1997-01-28 | Nisshin Oil Mills Ltd:The | 油脂含有飲食物 |
JPH0930962A (ja) | 1995-07-21 | 1997-02-04 | Nisshin Oil Mills Ltd:The | 医療用油脂含有組成物 |
US6200624B1 (en) | 1996-01-26 | 2001-03-13 | Abbott Laboratories | Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids |
CN1058845C (zh) | 1996-01-31 | 2000-11-29 | 高世虎 | 强化营养豆奶粉 |
GB9617847D0 (en) | 1996-08-27 | 1996-10-09 | Scotia Holdings Plc | Fatty acid treatment |
JP4034370B2 (ja) * | 1996-09-27 | 2008-01-16 | 雪印乳業株式会社 | 脳機能改善剤及び栄養組成物 |
JP4633204B2 (ja) | 1996-10-11 | 2011-02-16 | サントリーホールディングス株式会社 | アラキドン酸含有食用油脂およびそれを含有する食品 |
JPH10155459A (ja) | 1996-11-27 | 1998-06-16 | Suntory Ltd | アスタキサンチン含有飲食物 |
US6080787A (en) * | 1997-02-21 | 2000-06-27 | Abbott Laboratories | Methods for reducing the incidence of necrotizing enterocolitis |
FR2762993B1 (fr) * | 1997-05-06 | 1999-08-13 | Inst Rech Biolog Sa | Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique |
US5902807A (en) * | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
KR100255868B1 (ko) * | 1997-06-28 | 2000-05-01 | 김영환 | 2의 보수 복소수 곱셈기 |
DE69718455T2 (de) | 1997-07-22 | 2003-04-30 | Societe Des Produits Nestle S.A., Vevey | Lipidzusammensetzung für Säuglingsnährpräparat und Herstellungsverfahren |
JP2970804B2 (ja) | 1997-07-23 | 1999-11-02 | 株式会社フジクラ | 難燃性シート |
US6225444B1 (en) * | 1998-02-10 | 2001-05-01 | Protarga, Inc. | Neuroprotective peptides and uses thereof |
JP4175698B2 (ja) | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
AU775421B2 (en) | 1998-10-15 | 2004-07-29 | Dsm Ip Assets B.V. | Pufa supplements |
GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
JP2001031586A (ja) | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
WO2001085158A2 (en) | 2000-05-08 | 2001-11-15 | Forskarpatent I Syd Ab | Anandamide and structurally related lipids as vanilloid receptor modulators |
AU2001265186A1 (en) | 2000-05-30 | 2001-12-11 | The Brigham And Women's Hospital, Inc. | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions |
AU2001266289A1 (en) * | 2000-06-23 | 2002-01-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
GB0016045D0 (en) * | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
AU2001292586A1 (en) | 2000-09-07 | 2002-03-22 | University Of Maryland Biotechnology Institute | Use of arachidonic acid for enhanced culturing of fish larvae and broodstock |
ES2324640T3 (es) | 2001-03-09 | 2009-08-12 | Societe Des Produits Nestle S.A. | Aceite que contiene un o unos acido(s) graso(s) poliin-saturado(s) de cadena larga resultante de una biomasa, procedimiento de preparacion, alimento, composicion nutricional, cosmetica o farmaceutica que lo contiene. |
GB0111282D0 (en) | 2001-05-09 | 2001-06-27 | Laxdale Ltd | Potentiation of therapeutic effects of fatty acids |
CN1516592A (zh) | 2001-06-18 | 2004-07-28 | �����Ǽ���&������Դ����˾ | 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物 |
ATE457357T1 (de) | 2001-07-02 | 2010-02-15 | Suntory Holdings Ltd | Verfahren zur herstellung von fett mit triglyceridhaltiger hochungesättigter fettsäure |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
CA2456034A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
JP2003113120A (ja) | 2001-08-03 | 2003-04-18 | Takeda Chem Ind Ltd | 徐放性医薬 |
US6689810B2 (en) * | 2001-08-21 | 2004-02-10 | Cellular Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
CA2485116C (en) | 2002-05-03 | 2013-02-05 | Pronova Biocare As | Use of epa and dha in secondary prevention |
CA2498569C (en) | 2002-09-13 | 2016-11-29 | Suntory Limited | Process for production of transesterified oils/fats or triglycerides |
GB0221480D0 (en) | 2002-09-16 | 2002-10-23 | Laxdale Ltd | Treatment of anorexia nervosa (AN) and bulimia |
EP1542670B2 (en) * | 2002-09-24 | 2023-07-05 | Suntory Holdings Limited | Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities in adults |
US9782377B2 (en) | 2003-03-27 | 2017-10-10 | Suntory Holdings Limited | Composition for normalization of infradian rhythm |
WO2004091663A1 (ja) | 2003-04-18 | 2004-10-28 | Kyowa Hakko Kogyo Co., Ltd. | 神経再生薬 |
CH698539A8 (de) | 2003-08-18 | 2009-10-15 | Btg Int Ltd | Verbindungen mit ungesättigten Fettsäureresten zur Herstellung von Medikamenten zur Behandlung von multipler Sklerose. |
IL158552A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Lipids containing omega-3 fatty acids |
JP4522075B2 (ja) * | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
EP1713463A4 (en) | 2004-01-19 | 2009-03-18 | Martek Biosciences Corp | REELIN DYSFUNCTION OR DICTION AND ASSOCIATED TECHNIQUES |
JP4868199B2 (ja) | 2004-09-10 | 2012-02-01 | 学校法人鈴鹿医療科学大学 | サルビアノール酸bを有効成分とする神経幹細胞増殖剤 |
JP2006083136A (ja) | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
JP5697293B2 (ja) | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
-
2001
- 2001-08-02 JP JP2001235519A patent/JP2003048831A/ja not_active Withdrawn
-
2002
- 2002-01-29 KR KR1020177026429A patent/KR20170109693A/ko not_active Application Discontinuation
- 2002-01-29 CN CNA028192125A patent/CN1561206A/zh active Pending
- 2002-01-29 EP EP02716453A patent/EP1419768B1/en not_active Revoked
- 2002-01-29 CA CA2456049A patent/CA2456049C/en not_active Expired - Lifetime
- 2002-01-29 WO PCT/JP2002/000671 patent/WO2003013497A1/ja active Application Filing
- 2002-01-29 CN CNA200810131360XA patent/CN101336913A/zh active Pending
- 2002-01-29 ES ES02716453T patent/ES2369074T3/es not_active Expired - Lifetime
- 2002-01-29 US US10/485,456 patent/US10744146B2/en not_active Expired - Lifetime
- 2002-01-29 KR KR1020047001544A patent/KR101989390B1/ko active IP Right Grant
- 2002-01-29 DK DK02716453.2T patent/DK1419768T3/da active
- 2002-01-29 PT PT02716453T patent/PT1419768E/pt unknown
- 2002-01-29 AT AT02716453T patent/ATE520395T1/de active
-
2008
- 2008-03-05 AU AU2008201045A patent/AU2008201045B2/en not_active Expired
-
2011
- 2011-09-07 CY CY20111100859T patent/CY1111808T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2369074T3 (es) | 2011-11-25 |
WO2003013497A1 (fr) | 2003-02-20 |
CA2456049C (en) | 2012-10-16 |
EP1419768A4 (en) | 2005-07-06 |
AU2008201045B2 (en) | 2011-02-17 |
KR101989390B1 (ko) | 2019-06-14 |
JP2003048831A (ja) | 2003-02-21 |
DK1419768T3 (da) | 2011-09-12 |
CN1561206A (zh) | 2005-01-05 |
ATE520395T1 (de) | 2011-09-15 |
PT1419768E (pt) | 2011-10-13 |
EP1419768B1 (en) | 2011-08-17 |
AU2008201045A1 (en) | 2008-04-03 |
CA2456049A1 (en) | 2003-02-20 |
US20040266874A1 (en) | 2004-12-30 |
CN101336913A (zh) | 2009-01-07 |
US10744146B2 (en) | 2020-08-18 |
KR20040026697A (ko) | 2004-03-31 |
KR20170109693A (ko) | 2017-09-29 |
EP1419768A1 (en) | 2004-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111808T1 (el) | Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια | |
ATE475416T1 (de) | Fettalkohole und fettsäureester zur behandlung von entzündungen | |
BR0012320A (pt) | Composição de gorduras ou de óleos | |
ATE478129T1 (de) | Kerzenwachs auf triacylglycerin-basis | |
WO2002094210A3 (de) | Kosmetische mittel | |
BRPI0517095A (pt) | processos para preparação de composições de óleo | |
DE60233782D1 (de) | Lipasevarianten | |
EA201000400A1 (ru) | Твердые жировые композиции, содержащие полиненасыщенные жирные кислоты, и способы их получения и использования | |
MX2009004246A (es) | Composiciones antimicrobianas. | |
BR0112073A (pt) | Combinações terapêuticas de ácidos graxos | |
ATE382597T1 (de) | Analoga von omega-3-pufas abgeleiteten lipidmediatoren und anwendungsverfahren | |
BR0213546A (pt) | Composições ácidas de sanitização e limpeza contendo ácidos carboxìlicos protonados | |
ATE422350T1 (de) | Anisinsäure und glyceride enthaltende zusammensetzungen | |
BR0110664A (pt) | Composição de gordura alimentìcia escoável, e, uso de uma combinação de um éster de ácido cìtrico de glicerìdeos parciais de ácido graxo e um sal | |
AR045504A1 (es) | Composicion de ester ramificado | |
RU2009101326A (ru) | Препарат для наружного применения на кожу, содержащий тритерпеновую кислоту | |
WO2006111633A3 (fr) | Utilisation de la lecithine comme medicament dans le traitement du psoriasis | |
MX2009004339A (es) | Alcoholes de acido graso. | |
UY26303A1 (es) | Composiciones farmacéuticas para administración oral y tópica | |
ATE474547T1 (de) | O/w emulsion zur pflege der hand | |
BR0211590A (pt) | Composições de barra de limpeza | |
ATE138531T1 (de) | Triglyceride-zusammensetzungen gegen fettbleichen | |
SE0201566D0 (sv) | New composition | |
FR3090340B1 (fr) | Composition cosmétique pour fibres kératiniques | |
FR3090334B1 (fr) | Composition cosmétique pour fibres kératiniques |